Evolva Holding SA, a company traded on the SIX Swiss Stock Exchange, has agreed to acquire certain assets of Fluxome Sciences A/S, a privately held Danish company that is in reconstruction. The agreement is subject to creditor and court approval. Evolva has a proprietary, fermentation-based platform that allows innovative approaches to the production of ingredients for the food, beverage and consumer health sectors. Fluxome was established in 2002 as a spinoff from the Technical University of Denmark. The company produces nutritional ingredients using novel metabolic engineering and fermentation methods. In 2009, Fluxome opened a sales office in the United States and introduced its resveratrol product commercially. Evolva was a Presenting Company at NCN XI in October, 2012; Fluxome presented at NCN VIII in April, 2011.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news